DE4240430A1 - - Google Patents
Info
- Publication number
- DE4240430A1 DE4240430A1 DE4240430A DE4240430A DE4240430A1 DE 4240430 A1 DE4240430 A1 DE 4240430A1 DE 4240430 A DE4240430 A DE 4240430A DE 4240430 A DE4240430 A DE 4240430A DE 4240430 A1 DE4240430 A1 DE 4240430A1
- Authority
- DE
- Germany
- Prior art keywords
- weight
- carbonate
- sodium
- agent
- alkaline medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 57
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 33
- 150000001875 compounds Chemical class 0.000 claims description 30
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims description 28
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 27
- 239000003795 chemical substances by application Substances 0.000 claims description 27
- 229940079593 drug Drugs 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- -1 HMG-CoA compound Chemical class 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 20
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 17
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 17
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 17
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 17
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 17
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 15
- 239000002775 capsule Substances 0.000 claims description 15
- 239000002245 particle Substances 0.000 claims description 14
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 14
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 14
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 8
- 239000006185 dispersion Substances 0.000 claims description 8
- 229960000868 fluvastatin sodium Drugs 0.000 claims description 8
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 8
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 6
- 239000008177 pharmaceutical agent Substances 0.000 claims description 6
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 claims description 5
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 230000000087 stabilizing effect Effects 0.000 claims description 5
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 4
- 150000001768 cations Chemical class 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000001913 cellulose Substances 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000011872 intimate mixture Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 description 30
- 239000002253 acid Substances 0.000 description 29
- 229960003765 fluvastatin Drugs 0.000 description 20
- 239000003826 tablet Substances 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 13
- 239000000945 filler Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 11
- 210000004211 gastric acid Anatomy 0.000 description 11
- 239000008187 granular material Substances 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 9
- 238000003860 storage Methods 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- 239000000314 lubricant Substances 0.000 description 8
- 238000001035 drying Methods 0.000 description 7
- 239000007888 film coating Substances 0.000 description 7
- 238000009501 film coating Methods 0.000 description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 229920000881 Modified starch Polymers 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000005550 wet granulation Methods 0.000 description 5
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000012907 medicinal substance Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 3
- 229960003975 potassium Drugs 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 2
- 229940081735 acetylcellulose Drugs 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000000181 anti-adherent effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000007963 capsule composition Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000005056 compaction Methods 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052806 inorganic carbonate Inorganic materials 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000003605 opacifier Substances 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- COEZWFYORILMOM-UHFFFAOYSA-M sodium 4-[(2,4-dihydroxyphenyl)diazenyl]benzenesulfonate Chemical compound [Na+].OC1=CC(O)=CC=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 COEZWFYORILMOM-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 238000001238 wet grinding Methods 0.000 description 2
- BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- YZBOVSFWWNVKRJ-UHFFFAOYSA-N Monobutylphthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(O)=O YZBOVSFWWNVKRJ-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000004826 Synthetic adhesive Substances 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- GANNOFFDYMSBSZ-UHFFFAOYSA-N [AlH3].[Mg] Chemical class [AlH3].[Mg] GANNOFFDYMSBSZ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940024548 aluminum oxide Drugs 0.000 description 1
- RJZNFXWQRHAVBP-UHFFFAOYSA-I aluminum;magnesium;pentahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Al+3] RJZNFXWQRHAVBP-UHFFFAOYSA-I 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- QWDJLDTYWNBUKE-UHFFFAOYSA-L magnesium bicarbonate Chemical compound [Mg+2].OC([O-])=O.OC([O-])=O QWDJLDTYWNBUKE-UHFFFAOYSA-L 0.000 description 1
- 239000002370 magnesium bicarbonate Substances 0.000 description 1
- 229910000022 magnesium bicarbonate Inorganic materials 0.000 description 1
- 235000014824 magnesium bicarbonate Nutrition 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008030 superplasticizer Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4245089A DE4245089B4 (de) | 1991-12-12 | 1992-12-02 | Stabilisiertes pharmazeutisches Mittel, enthaltend einen HMG-CoA-Reduktase-Inhibitor als Wirkstoff |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80566791A | 1991-12-12 | 1991-12-12 | |
| US07/805,667 | 1991-12-12 | ||
| DE4245089A DE4245089B4 (de) | 1991-12-12 | 1992-12-02 | Stabilisiertes pharmazeutisches Mittel, enthaltend einen HMG-CoA-Reduktase-Inhibitor als Wirkstoff |
| CN93100650A CN1041794C (zh) | 1991-12-12 | 1993-01-30 | 含有一种β－羟基－β－甲基戊二酸单酰辅酶A还原酶抑制剂的稳定的药物组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE4240430A1 true DE4240430A1 (enEXAMPLES) | 1993-06-17 |
| DE4240430B4 DE4240430B4 (de) | 2007-12-27 |
Family
ID=36808687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE4240430A Expired - Lifetime DE4240430B4 (de) | 1991-12-12 | 1992-12-02 | Stabilisiertes pharmazeutisches Mittel, enthaltend einen HMG-CoA-Reduktase-Inhibitor Wirkstoff |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US5356896A (enEXAMPLES) |
| EP (1) | EP0547000B1 (enEXAMPLES) |
| JP (1) | JP2774037B2 (enEXAMPLES) |
| KR (1) | KR100253824B1 (enEXAMPLES) |
| CN (1) | CN1041794C (enEXAMPLES) |
| AT (1) | AT401870B (enEXAMPLES) |
| AU (1) | AU661075B2 (enEXAMPLES) |
| CA (1) | CA2085037C (enEXAMPLES) |
| CH (1) | CH684309A5 (enEXAMPLES) |
| CY (1) | CY1994A (enEXAMPLES) |
| CZ (1) | CZ287776B6 (enEXAMPLES) |
| DE (1) | DE4240430B4 (enEXAMPLES) |
| DK (1) | DK0547000T3 (enEXAMPLES) |
| ES (1) | ES2142819T3 (enEXAMPLES) |
| FI (1) | FI114284B (enEXAMPLES) |
| FR (1) | FR2684876B1 (enEXAMPLES) |
| GB (1) | GB2262229B (enEXAMPLES) |
| GR (1) | GR3032929T3 (enEXAMPLES) |
| HK (1) | HK25597A (enEXAMPLES) |
| HU (2) | HU217629B (enEXAMPLES) |
| IL (1) | IL104041A (enEXAMPLES) |
| IT (1) | IT1256698B (enEXAMPLES) |
| LU (1) | LU88201A1 (enEXAMPLES) |
| MX (1) | MX9207152A (enEXAMPLES) |
| NO (1) | NO302099B1 (enEXAMPLES) |
| NZ (1) | NZ245421A (enEXAMPLES) |
| PT (1) | PT547000E (enEXAMPLES) |
| RO (1) | RO111542B1 (enEXAMPLES) |
| RU (1) | RU2121835C1 (enEXAMPLES) |
| SK (1) | SK281710B6 (enEXAMPLES) |
| ZA (1) | ZA929642B (enEXAMPLES) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10038110A1 (de) * | 2000-01-26 | 2001-08-23 | Astrazeneca Ab | Pharmazeutische Zusammensetzungen |
Families Citing this family (191)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6300362B1 (en) * | 1990-07-25 | 2001-10-09 | Novartis Ag (Formerly Sandoz Ltd.) | Stabilized pharmaceutical compositions comprising acid donors |
| DE4243279A1 (de) * | 1992-12-21 | 1994-06-23 | Bayer Ag | Substituierte Triole |
| US5399356A (en) * | 1994-03-24 | 1995-03-21 | The Procter & Gamble Company | Process for making solid dose forms containing bismuth |
| RU2152209C1 (ru) * | 1994-05-13 | 2000-07-10 | Егис Гиогисзергуар Р.Т. | Гемфиброзил-содержащие фармацевтические композиции |
| CA2229605A1 (en) | 1995-08-17 | 1997-02-27 | The Regents Of The University Of California | Genes and proteins controlling cholesterol synthesis |
| WO1997023200A1 (en) * | 1995-12-22 | 1997-07-03 | Kowa Company, Ltd. | Pharmaceutical composition stabilized with a basic agent |
| AU713277B2 (en) * | 1996-04-05 | 1999-11-25 | Takeda Pharmaceutical Company Limited | Pharmaceutical combination containing a compound having angiotensin II and antagonistic activity |
| CA2251092A1 (en) | 1996-04-16 | 1997-10-23 | Takeda Chemical Industries, Ltd. | D-mannitol and its preparation |
| JP3126683B2 (ja) | 1996-04-16 | 2001-01-22 | 武田薬品工業株式会社 | Ｄ−マンニトールおよびその製造法 |
| PT907639E (pt) * | 1996-06-24 | 2003-06-30 | Novartis Ag | Compostos polimorficos |
| SE9603667D0 (sv) * | 1996-10-08 | 1996-10-08 | Astra Ab | Pharmaceutical compositions |
| SE9603668D0 (sv) * | 1996-10-08 | 1996-10-08 | Astra Ab | Pharmaceutical compositions |
| DE19725391A1 (de) * | 1997-06-16 | 1998-12-17 | Bayer Ag | Verfahren zur Herstellung von Arzneimittel, enthaltend HMG-CoA-Reduktase-Inhibitoren |
| US6465477B1 (en) * | 1997-08-18 | 2002-10-15 | Kowa Company, Ltd. | Stable pharmaceutical composition |
| US20060141036A1 (en) * | 1997-12-12 | 2006-06-29 | Andrx Labs Llc | HMG-CoA reductase inhibitor extended release formulation |
| US6235311B1 (en) * | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
| US20010014352A1 (en) | 1998-05-27 | 2001-08-16 | Udit Batra | Compressed tablet formulation |
| US5997905A (en) * | 1998-09-04 | 1999-12-07 | Mcneil-Ppc | Preparation of pharmaceutically active particles |
| SI20070A (sl) | 1998-09-18 | 2000-04-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Nove soli inhibitorjev HMG-CoA reduktaze |
| US20020169145A1 (en) * | 1998-10-14 | 2002-11-14 | Rajen Shah | Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent |
| AU767154B2 (en) | 1998-11-20 | 2003-10-30 | Skyepharma Canada Inc. | Dispersible phospholipid stabilized microparticles |
| TWI230618B (en) * | 1998-12-15 | 2005-04-11 | Gilead Sciences Inc | Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same |
| SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
| US6569461B1 (en) | 1999-03-08 | 2003-05-27 | Merck & Co., Inc. | Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors |
| EP1036563A1 (en) * | 1999-03-08 | 2000-09-20 | MERCK & CO. INC. | Delayed-release oral formulation of dihydroxy open acid simvastatin and salts and esters thereof |
| JP2002538202A (ja) * | 1999-03-08 | 2002-11-12 | メルク エンド カムパニー インコーポレーテッド | ＨＭＧ−ＣｏＡレダクターゼ阻害剤のジヒドロキシオープンアシッド及びその塩 |
| WO2000067737A2 (en) * | 1999-05-07 | 2000-11-16 | The Brigham And Women's Hospital, Inc. | USE OF HMGCoA REDUCTASE INHIBITORS IN THE PREVENTION OF DISEASES WHOSE PATHOGENESIS IS DEPENDENT ON NEOVASCULARIZATION |
| WO2001032161A2 (en) * | 1999-11-04 | 2001-05-10 | Andrx Corporation | Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders |
| US20020107173A1 (en) * | 1999-11-04 | 2002-08-08 | Lawrence Friedhoff | Method of treating amyloid beta precursor disorders |
| WO2001056596A1 (en) | 2000-02-04 | 2001-08-09 | Children's Hospital Research Foundation | Use of lysosomal acid lipase for treating atherosclerosis and related diseases |
| IL152021A0 (en) * | 2000-04-11 | 2003-04-10 | Sankyo Co | Pharmaceutical compositions containing pyridine derivatives |
| US6242003B1 (en) * | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
| GB0011163D0 (en) * | 2000-05-10 | 2000-06-28 | Astrazeneca Ab | Chemical compound |
| JP2003535077A (ja) * | 2000-05-26 | 2003-11-25 | チバ スペシャルティ ケミカルズ ホールディング インコーポレーテッド | インドール誘導体を製造する方法、および該方法の中間体 |
| US6806290B2 (en) | 2000-06-09 | 2004-10-19 | Lek Pharmaceuticals D.D. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
| AU2000249434B2 (en) * | 2000-06-09 | 2006-02-02 | Lek Pharmaceuticals D.D. | Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
| ATE418979T2 (de) | 2000-06-09 | 2009-01-15 | Lek Pharmaceuticals | Stabilisiertes arzneimittel und arzneizubereitung |
| US8586094B2 (en) | 2000-09-20 | 2013-11-19 | Jagotec Ag | Coated tablets |
| EP1379167A1 (en) | 2001-04-06 | 2004-01-14 | Medic4all Inc. | A physiological monitoring system for a computational device of a human subject |
| US20060127474A1 (en) | 2001-04-11 | 2006-06-15 | Oskar Kalb | Pharmaceutical compositions comprising fluvastatin |
| GB0111077D0 (en) * | 2001-05-04 | 2001-06-27 | Biochemie Gmbh | Organic compounds |
| US6699886B2 (en) * | 2001-05-31 | 2004-03-02 | Cellegy Pharmaceuticals, Inc. | Store operated calcium influx inhibitors and methods of use |
| EP1404303A4 (en) * | 2001-06-21 | 2006-03-15 | Andrx Pharmaceuticals Inc | STABLE PHARMACEUTICAL COMPOSITIONS BASED ON PRAVASTATIN |
| JP4681808B2 (ja) * | 2001-08-03 | 2011-05-11 | チバ ホールディング インコーポレーテッド | 結晶形 |
| EP2269609A3 (en) | 2001-10-16 | 2012-07-11 | Sloan-Kettering Institute for Cancer Research | Treatment of neurodegenerative diseases and cancer of the brain with SAHA |
| US7183321B2 (en) * | 2001-12-17 | 2007-02-27 | Bristol-Myers Squibb Company | Antidiabetic formulation and method |
| CA2475722A1 (en) * | 2002-02-14 | 2003-08-21 | Romi Barat Singh | Formulations of atorvastatin stabilized with alkali metal additions |
| US7148257B2 (en) | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
| US7456219B2 (en) | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
| RU2320331C2 (ru) | 2002-03-04 | 2008-03-27 | МЕРК ЭйчДиЭйСи Рисерч, ЛЛС. | Способ индукции конечной дифференцировки |
| JP2005528400A (ja) * | 2002-04-16 | 2005-09-22 | メルク エンド カムパニー インコーポレーテッド | チロシンキナーゼ活性を有する塩の固体形態 |
| DK2336359T3 (en) | 2002-05-09 | 2016-05-30 | Brigham & Womens Hospital | 1L1RL-1 as cardiovascular disease marker |
| CA2385529A1 (en) * | 2002-05-21 | 2003-11-21 | Bernard Charles Sherman | Stable dosage forms comprising atorvastatin calcium |
| DK1515717T3 (da) * | 2002-06-13 | 2009-02-09 | Novartis Ag | Calciumsalte af indolafledte statiner |
| US20040006109A1 (en) * | 2002-07-03 | 2004-01-08 | Rajneesh Taneja | Liquid dosage forms of non-enterically coated acid-labile drugs |
| US20060019269A1 (en) * | 2002-10-17 | 2006-01-26 | Decode Genetics, Inc. | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment |
| US20080293750A1 (en) * | 2002-10-17 | 2008-11-27 | Anna Helgadottir | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment |
| US20040198800A1 (en) * | 2002-12-19 | 2004-10-07 | Geoffrey Allan | Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents |
| EP1585500B8 (en) * | 2002-12-20 | 2017-07-26 | Auritec Pharmaceuticals | Coated particles for sustained-release pharmaceutical administration |
| US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
| ATE461700T1 (de) | 2002-12-20 | 2010-04-15 | Pfizer Prod Inc | Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer |
| EP1603554A1 (en) * | 2003-03-17 | 2005-12-14 | Japan Tobacco Inc. | Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate |
| TWI393560B (zh) * | 2003-05-02 | 2013-04-21 | Japan Tobacco Inc | 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合 |
| US7166638B2 (en) * | 2003-05-27 | 2007-01-23 | Nicox S.A. | Statin derivatives |
| AU2004242777B2 (en) | 2003-05-30 | 2011-05-12 | Ranbaxy Laboratories Limited | Substituted pyrrole derivatives and their use as HMG-Co inhibitors |
| EP1780200A1 (en) * | 2003-06-18 | 2007-05-02 | Teva Pharmaceutical Industries Limited | A crystalline form of fluvastatin sodium and a process for preparing it |
| WO2005000276A1 (en) * | 2003-06-25 | 2005-01-06 | Novartis Ag | Tablet comprising fluvastatin and carmellose calcium |
| JP2007077174A (ja) * | 2003-06-25 | 2007-03-29 | Novartis Ag | フルバスタチン含有錠剤 |
| GB2404336A (en) * | 2003-07-30 | 2005-02-02 | Cipla Ltd | Stabilisation of therapeutic agents using a carbonate salt of an amino acid, preferably in the presence of a saccharide, & pharmaceutical compositions thereof |
| AU2004266740B2 (en) | 2003-08-21 | 2010-08-26 | Merck Frosst Canada Ltd | Cathepsin cysteine protease inhibitors |
| EP1510208A1 (en) | 2003-08-22 | 2005-03-02 | Fournier Laboratories Ireland Limited | Pharmaceutical composition comprising a combination of metformin and statin |
| EP2428516A1 (en) | 2003-11-19 | 2012-03-14 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| WO2005053683A1 (en) * | 2003-11-26 | 2005-06-16 | Duke University | A method of preventing or treating glaucoma |
| JPWO2005063294A1 (ja) | 2003-12-30 | 2007-12-13 | 興和株式会社 | γ−セクレターゼ複合体形成阻害剤 |
| US8163797B2 (en) * | 2003-12-31 | 2012-04-24 | Actavis Elizabeth Llc | Method of treating with stable pravastatin formulation |
| US20100216863A1 (en) * | 2004-01-30 | 2010-08-26 | Decode Genetics Ehf. | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment |
| US8158362B2 (en) * | 2005-03-30 | 2012-04-17 | Decode Genetics Ehf. | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype |
| US7803838B2 (en) * | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
| WO2006017698A2 (en) * | 2004-08-06 | 2006-02-16 | Transform Pharmaceuticals, Inc. | Novel statin pharmaceutical compositions and related methods of treatment |
| US20090042979A1 (en) * | 2004-08-06 | 2009-02-12 | Transform Pharmaceuticals Inc. | Novel Statin Pharmaceutical Compositions and Related Methods of Treatment |
| SG155189A1 (en) * | 2004-08-06 | 2009-09-30 | Transform Pharmaceuticals Inc | Novel fenofibrate formulations and related methods of treatment |
| DE102004042139B4 (de) * | 2004-08-31 | 2009-06-10 | Aristocon Verwaltungs- Gmbh | Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit |
| AU2005294165B2 (en) | 2004-10-06 | 2012-02-02 | The Brigham And Women's Hospital, Inc. | Relevance of achieved levels of markers of systemic inflammation following treatment |
| ES2255426B1 (es) * | 2004-10-19 | 2007-08-16 | Gp Pharm, S.A. | Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa). |
| JP2008523065A (ja) | 2004-12-09 | 2008-07-03 | メルク エンド カムパニー インコーポレーテッド | エストロゲン受容体モジュレーター |
| US20070129402A1 (en) * | 2004-12-27 | 2007-06-07 | Eisai Research Institute | Sustained release formulations |
| US8481565B2 (en) | 2004-12-27 | 2013-07-09 | Eisai R&D Management Co., Ltd. | Method for stabilizing anti-dementia drug |
| NZ560386A (en) * | 2005-01-31 | 2009-12-24 | Mylan Lab Inc | Pharmaceutical composition comprising hydroxylated nebivolol |
| PT1855674E (pt) | 2005-03-02 | 2014-10-08 | Merck Canada Inc | Composição para a inibição de catepsina k |
| US20060229277A1 (en) * | 2005-04-08 | 2006-10-12 | Orbus Pharma, Inc. | Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor |
| BRPI0608780A2 (pt) * | 2005-04-28 | 2010-11-09 | Eisai R&D Man Co Ltd | composição contendo fármaco anti-demência |
| ATE550019T1 (de) | 2005-05-17 | 2012-04-15 | Merck Sharp & Dohme | Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs |
| JP2008545742A (ja) | 2005-05-31 | 2008-12-18 | マイラン ラボラトリーズ インク． | ネビボロールを含む組成物 |
| WO2007074406A2 (en) | 2005-07-11 | 2007-07-05 | Pharmena North America Inc. | Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative |
| WO2007016757A1 (en) * | 2005-08-05 | 2007-02-15 | Orbus Pharma Inc. | Stabilized extended release pharmeceutical compositions comprising an hmg-coa reductase inhibitor |
| PE20070427A1 (es) * | 2005-08-30 | 2007-04-21 | Novartis Ag | Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas |
| US8119358B2 (en) | 2005-10-11 | 2012-02-21 | Tethys Bioscience, Inc. | Diabetes-related biomarkers and methods of use thereof |
| CA2627599A1 (en) | 2005-11-08 | 2007-05-18 | Ranbaxy Laboratories Limited | Process for (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt |
| US20090247603A1 (en) * | 2005-12-23 | 2009-10-01 | Orbus Pharma, Inc. | Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor |
| EP1905424A3 (en) * | 2006-02-02 | 2008-04-30 | Ranbaxy Laboratories Limited | Process for the preparation of a pharmaceutical composition comprising stabilized statin particles |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| CA2642195A1 (en) * | 2006-02-24 | 2007-09-07 | Teva Pharmaceutical Industries Ltd. | Fluvastatin sodium pharmaceutical compositions |
| TW200744583A (en) * | 2006-03-14 | 2007-12-16 | Ranbaxy Lab Ltd | Statin stabilizing dosage formulations |
| US7553854B2 (en) | 2006-04-19 | 2009-06-30 | Novartis Vaccines And Diagnostics, Inc. | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling |
| EP2924440A3 (en) | 2006-06-07 | 2016-03-09 | Health Diagnostic Laboratory, Inc. | Markers associated with arteriovascular events and methods of use thereof |
| EP2452683A3 (en) | 2006-06-26 | 2012-08-22 | Amgen Inc. | Methods for treating atherosclerosis |
| ES2532595T3 (es) * | 2006-08-30 | 2015-03-30 | Kyushu University, National University Corporation | Composición farmacéutica que contiene una nanopartícula de estatina encapsulada |
| WO2008039327A2 (en) | 2006-09-22 | 2008-04-03 | Merck & Co., Inc. | Method of treatment using fatty acid synthesis inhibitors |
| MX2020001259A (es) * | 2006-09-26 | 2020-03-20 | Novartis Ag | Composiciones farmaceuticas que comprenden un modulador de s1p. |
| EP1923053A1 (en) * | 2006-09-27 | 2008-05-21 | Novartis AG | Pharmaceutical compositions comprising nilotinib or its salt |
| EP1911441A3 (en) * | 2006-10-11 | 2008-08-06 | Lupin Limited | Controlled release color stable pharmaceutical dosage form of HMG-COA reductase inhibitors, free of alkalizing or buffering agents |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| US20110052688A1 (en) * | 2006-11-21 | 2011-03-03 | San-Laung Chow | Solid dispersion composition |
| US20080132560A1 (en) * | 2006-11-21 | 2008-06-05 | San-Laung Chow | Solid dispersion composition |
| WO2008084261A1 (en) | 2007-01-10 | 2008-07-17 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
| CA2679659C (en) | 2007-03-01 | 2016-01-19 | Novartis Ag | Pim kinase inhibitors and methods of their use |
| US20080249141A1 (en) * | 2007-04-06 | 2008-10-09 | Palepu Nageswara R | Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters |
| US20080248115A1 (en) * | 2007-04-09 | 2008-10-09 | Palepu Nageswara R | Combinations of statins and anti-obesity agent |
| US20080249156A1 (en) * | 2007-04-09 | 2008-10-09 | Palepu Nageswara R | Combinations of statins and anti-obesity agent and glitazones |
| AU2008242764B2 (en) | 2007-04-18 | 2013-10-24 | Tethys Bioscience, Inc. | Diabetes-related biomarkers and methods of use thereof |
| CN101754965B (zh) | 2007-05-21 | 2014-03-19 | 诺华股份有限公司 | Csf-1r抑制剂、组合物及使用方法 |
| JP5501227B2 (ja) | 2007-06-27 | 2014-05-21 | メルク・シャープ・アンド・ドーム・コーポレーション | ヒストンデアセチラーゼ阻害剤としての４−カルボキシベンジルアミノ誘導体 |
| MY159075A (en) | 2007-07-26 | 2016-12-15 | Amgen Inc | Modified lecithin-cholesterol acyltransferase enzymes |
| CN101945853B (zh) | 2007-12-21 | 2014-08-20 | 配体药物公司 | 选择性雄激素受体调节剂(sarm)及其应用 |
| EP2138165A1 (en) | 2008-06-27 | 2009-12-30 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising a statin |
| ES2657416T3 (es) * | 2008-06-27 | 2018-03-05 | Krka, Torvarna Zdravil, D.D., Novo Mesto | Composición farmacéutica que comprende una estatina |
| US20110098315A1 (en) * | 2008-06-27 | 2011-04-28 | Farhad Sayyad Farshi | Pharmaceutical compositions of rosuvastatin calcium |
| WO2010093601A1 (en) | 2009-02-10 | 2010-08-19 | Metabasis Therapeutics, Inc. | Novel sulfonic acid-containing thyromimetics, and methods for their use |
| JP2012096998A (ja) * | 2009-02-27 | 2012-05-24 | Kowa Co | 安定なカプセル製剤及びその製造方法 |
| EP2413932A4 (en) | 2009-04-01 | 2012-09-19 | Merck Sharp & Dohme | INHIBITORS OF AKT ACTIVITY |
| TR200904341A2 (tr) | 2009-06-03 | 2010-12-21 | Bi̇lgi̇ç Mahmut | Rosuvastatin kalsiyum içeren kararlı farmasötik bileşimler. |
| NZ599343A (en) | 2009-10-14 | 2014-05-30 | Merck Sharp & Dohme | Substituted piperidines that increase p53 activity and the uses thereof |
| US8632819B2 (en) * | 2009-12-22 | 2014-01-21 | Fmc Corporation | Microcrystalline cellulose and calcium carbonate compositions useful as recompactible pharmaceutical excipients |
| WO2011094730A2 (en) | 2010-02-01 | 2011-08-04 | The Hospital For Sick Children | Remote ischemic conditioning for treatment and reventon of restenosis |
| SG10201502031XA (en) | 2010-03-31 | 2015-05-28 | Hospital For Sick Children | Use of remote ischemic conditioning to improve outcome after myocardial infarction |
| RU2012147442A (ru) | 2010-04-08 | 2014-05-20 | Дзе Хоспитал Фор Сик Чилдрен | Применение дистантного ишемического кондиционирования при травматическом повреждении |
| US8372877B2 (en) | 2010-04-16 | 2013-02-12 | Cumberland Pharmaceuticals | Stabilized statin formulations |
| TR201009397A2 (tr) | 2010-11-11 | 2012-05-21 | Bi̇lgi̇ç Mahmut | Rosuvastatin içeren farmasötik bileşimler. |
| EP2584903B1 (en) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| JP5829607B2 (ja) * | 2010-06-30 | 2015-12-09 | 持田製薬株式会社 | ω３脂肪酸の配合製剤 |
| EP2601293B1 (en) | 2010-08-02 | 2017-12-06 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| JP5792299B2 (ja) * | 2010-08-04 | 2015-10-07 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 神経因性疼痛の治療のための６’−フルオロ−（Ｎ−メチル−又はＮ，Ｎ−ジメチル−）−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンを含む医薬剤形 |
| CA2807307C (en) | 2010-08-17 | 2021-02-09 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina) |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| WO2012036997A1 (en) | 2010-09-16 | 2012-03-22 | Schering Corporation | Fused pyrazole derivatives as novel erk inhibitors |
| JPWO2012046772A1 (ja) | 2010-10-06 | 2014-02-24 | 国立大学法人 東京大学 | リンパ浮腫予防治療剤 |
| EP3766975A1 (en) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| US9351965B2 (en) | 2010-12-21 | 2016-05-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| US8791162B2 (en) | 2011-02-14 | 2014-07-29 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| JP5988963B2 (ja) | 2011-04-12 | 2016-09-07 | 沢井製薬株式会社 | ピタバスタチン含有製剤及びその製造方法 |
| JP2014514321A (ja) | 2011-04-21 | 2014-06-19 | メルク・シャープ・アンド・ドーム・コーポレーション | インスリン様増殖因子１受容体阻害剤 |
| WO2012153181A1 (en) * | 2011-05-11 | 2012-11-15 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical composition comprising pitavastatin or its pharmaceutically acceptable salts |
| KR101830977B1 (ko) * | 2011-06-30 | 2018-02-21 | 한미약품 주식회사 | 오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제 |
| EP2770987B1 (en) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| MX368200B (es) | 2011-12-08 | 2019-09-24 | Amgen Inc | Proteinas de union al antigeno lecitin colesterol aciltransferasas humanas agonistas y su uso en terapia. |
| US20150299696A1 (en) | 2012-05-02 | 2015-10-22 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
| CA2881563C (en) | 2012-08-01 | 2021-07-20 | Zahra TAVAKOLI | Free flowing, frozen compositions comprising a therapeutic agent |
| WO2014024268A1 (ja) | 2012-08-08 | 2014-02-13 | 興和株式会社 | 医薬 |
| RU2660429C2 (ru) | 2012-09-28 | 2018-07-06 | Мерк Шарп И Доум Корп. | Новые соединения, которые являются ингибиторами erk |
| ME02925B (me) | 2012-11-28 | 2018-04-20 | Merck Sharp & Dohme | Kompozicije i postupci za liječenje kancera |
| MX373639B (es) | 2012-12-20 | 2020-05-04 | Merck Sharp & Dohme | Imidazopiridinas sustituidas como inhibidores de doble minuto 2 humana. |
| US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
| TWI686213B (zh) | 2013-03-21 | 2020-03-01 | 美商優普順藥物公司美國分部 | 可注射持續釋放組合物及使用其治療關節之發炎及與發炎有關之疼痛之方法 |
| CN104069502B (zh) * | 2013-03-29 | 2018-02-16 | 北京罗诺强施医药技术研发中心有限公司 | 复合骨架材料及其药物组合物 |
| RO129060B1 (ro) * | 2013-04-25 | 2014-11-28 | Antibiotice S.A. | Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă |
| KR101597004B1 (ko) | 2013-07-25 | 2016-02-23 | 씨제이헬스케어 주식회사 | 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제 |
| US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| EP3055314B1 (en) | 2013-10-08 | 2018-09-12 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| WO2015051479A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| GB201319791D0 (en) * | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
| US10441567B2 (en) | 2014-01-17 | 2019-10-15 | Ligand Pharmaceuticals Incorporated | Methods and compositions for modulating hormone levels |
| WO2015120580A1 (en) | 2014-02-11 | 2015-08-20 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| WO2015185240A1 (en) | 2014-06-04 | 2015-12-10 | Sigma-Tau Industrire Farmaceutiche Riunite S.P.A. | Compositions containing simvastatin in omega-3 polyunsaturated fatty acids |
| JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
| KR20170083071A (ko) | 2014-11-11 | 2017-07-17 | 시오노기 앤드 컴파니, 리미티드 | 광에 대해서 불안정한 약물을 함유하는 다층 정제 |
| SG11201803156TA (en) | 2015-10-27 | 2018-05-30 | Eupraxia Pharmaceuticals Inc | Sustained release formulations of local anesthetics |
| US10975084B2 (en) | 2016-10-12 | 2021-04-13 | Merck Sharp & Dohme Corp. | KDM5 inhibitors |
| RU2648445C1 (ru) * | 2016-11-03 | 2018-03-26 | Светлана Асылхановна Астафьева | 6-(3,3- диметил-3,4-дигидроизохинолин-1-ил) аминогексановая кислота и фармацевтическая композиция на ёе основе, обладающие анальгетической активностью |
| WO2019094312A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| KR101954568B1 (ko) * | 2018-01-22 | 2019-03-05 | 한미약품 주식회사 | 오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제 |
| MX2021001486A (es) | 2018-08-07 | 2021-07-15 | Merck Sharp & Dohme Llc | Inhibidores prmt5. |
| US11981701B2 (en) | 2018-08-07 | 2024-05-14 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| JP2022529341A (ja) | 2019-04-19 | 2022-06-21 | リガンド・ファーマシューティカルズ・インコーポレイテッド | 化合物の結晶形、および化合物の結晶形を生成する方法 |
| WO2021126728A1 (en) | 2019-12-17 | 2021-06-24 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| US20230108452A1 (en) | 2019-12-17 | 2023-04-06 | Merck Sharp & Dohme Llc | Prmt5 inhibitors |
| AU2024228641A1 (en) | 2023-03-02 | 2025-07-24 | Carcimun Biotech Gmbh | Means and methods for diagnosing cancer and/or an acute inflammatory disease |
| WO2025147589A1 (en) | 2024-01-05 | 2025-07-10 | Osanni Bio, Inc. | Implants, compositions, and methods for treating retinal diseases and disorders |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3865935A (en) * | 1972-08-10 | 1975-02-11 | Abbott Lab | Tableting of erythromycin base |
| US3952096A (en) * | 1973-06-15 | 1976-04-20 | Bristol-Myers Company | Mixture of calcium carbonate and calcium-α-p-chlorophenoxyisobutyrate as an antihyperlipemic agent |
| US3891755A (en) * | 1973-07-11 | 1975-06-24 | Abbott Lab | Dosage formulation for erythromycin cetyl sulfate |
| US4342767A (en) * | 1980-01-23 | 1982-08-03 | Merck & Co., Inc. | Hypocholesteremic fermentation products |
| HU204253B (en) * | 1982-11-22 | 1991-12-30 | Sandoz Ag | Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them |
| US4739073A (en) * | 1983-11-04 | 1988-04-19 | Sandoz Pharmaceuticals Corp. | Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof |
| US4744987A (en) * | 1985-03-08 | 1988-05-17 | Fmc Corporation | Coprocessed microcrystalline cellulose and calcium carbonate composition and its preparation |
| US4671953A (en) * | 1985-05-01 | 1987-06-09 | University Of Utah Research Foundation | Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics |
| DE3524572A1 (de) * | 1985-07-10 | 1987-01-15 | Thomae Gmbh Dr K | Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung |
| CA1327010C (en) * | 1986-02-13 | 1994-02-15 | Tadashi Makino | Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production |
| GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| GB2189699A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| US4929605A (en) * | 1987-10-07 | 1990-05-29 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical composition for piperidinoalkanol derivatives |
| US5030447A (en) * | 1988-03-31 | 1991-07-09 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions having good stability |
| US4997658A (en) * | 1988-11-21 | 1991-03-05 | Merck & Co., Inc. | Method for enhancing the lowering of plasma cholesterol levels |
| US4933165A (en) * | 1989-01-18 | 1990-06-12 | Merck & Co., Inc. | Coenzyme Q10 with HMG-CoA reductase inhibitors |
| US5004651A (en) * | 1989-01-24 | 1991-04-02 | Abbott Laboratories | Stabilizing system for solid dosage forms |
| CA2016467A1 (en) * | 1989-06-05 | 1990-12-05 | Martin Eisman | Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor |
| CA2042526A1 (en) * | 1990-06-11 | 1991-12-12 | Adeoye Y. Olukotun | Method for preventing a second heart attack employing an hmg coa reductase inhibitor |
-
1992
- 1992-11-30 HU HU9203780A patent/HU217629B/hu unknown
- 1992-11-30 HU HU9203780A patent/HU9203780D0/hu unknown
- 1992-12-02 DE DE4240430A patent/DE4240430B4/de not_active Expired - Lifetime
- 1992-12-04 IT ITRM920870A patent/IT1256698B/it active IP Right Grant
- 1992-12-07 CH CH3751/92A patent/CH684309A5/de not_active IP Right Cessation
- 1992-12-08 GB GB9225659A patent/GB2262229B/en not_active Expired - Lifetime
- 1992-12-08 ES ES92810962T patent/ES2142819T3/es not_active Expired - Lifetime
- 1992-12-08 EP EP92810962A patent/EP0547000B1/en not_active Expired - Lifetime
- 1992-12-08 DK DK92810962T patent/DK0547000T3/da active
- 1992-12-08 PT PT92810962T patent/PT547000E/pt unknown
- 1992-12-10 MX MX9207152A patent/MX9207152A/es unknown
- 1992-12-10 KR KR1019920023818A patent/KR100253824B1/ko not_active Expired - Lifetime
- 1992-12-10 RO RO92-01545A patent/RO111542B1/ro unknown
- 1992-12-10 CA CA002085037A patent/CA2085037C/en not_active Expired - Lifetime
- 1992-12-10 FI FI925615A patent/FI114284B/fi not_active IP Right Cessation
- 1992-12-10 NO NO924768A patent/NO302099B1/no not_active IP Right Cessation
- 1992-12-10 SK SK3633-92A patent/SK281710B6/sk not_active IP Right Cessation
- 1992-12-10 CZ CS19923633A patent/CZ287776B6/cs not_active IP Right Cessation
- 1992-12-10 NZ NZ245421A patent/NZ245421A/en unknown
- 1992-12-10 JP JP4352222A patent/JP2774037B2/ja not_active Expired - Lifetime
- 1992-12-10 IL IL10404192A patent/IL104041A/en not_active IP Right Cessation
- 1992-12-10 AU AU30069/92A patent/AU661075B2/en not_active Expired
- 1992-12-11 RU RU92004564A patent/RU2121835C1/ru active
- 1992-12-11 ZA ZA929642A patent/ZA929642B/xx unknown
- 1992-12-11 LU LU88201A patent/LU88201A1/fr unknown
- 1992-12-11 AT AT0244992A patent/AT401870B/de not_active IP Right Cessation
- 1992-12-14 FR FR9215142A patent/FR2684876B1/fr not_active Expired - Lifetime
- 1992-12-22 US US07/995,252 patent/US5356896A/en not_active Expired - Lifetime
-
1993
- 1993-01-30 CN CN93100650A patent/CN1041794C/zh not_active Expired - Lifetime
-
1997
- 1997-03-06 HK HK25597A patent/HK25597A/xx not_active IP Right Cessation
- 1997-09-05 CY CY199497A patent/CY1994A/en unknown
-
2000
- 2000-03-10 GR GR20000400625T patent/GR3032929T3/el unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10038110A1 (de) * | 2000-01-26 | 2001-08-23 | Astrazeneca Ab | Pharmazeutische Zusammensetzungen |
| DE10038110B4 (de) * | 2000-01-26 | 2006-06-29 | Astrazeneca Ab | Pharmazeutische Zusammensetzungen |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AT401870B (de) | Stabilisiertes pharmazeutisches mittel, enthaltend einen hmg-coa-reduktase-inhibitor wirkstoff | |
| EP0108898B1 (de) | Neue orale Mopidamolformen | |
| EP0299211B1 (de) | DHP-Manteltablette | |
| DE69625046T2 (de) | Pharmazeutische zusammensetzung stabilisiert mit einem basischen medium | |
| EP0720473B1 (de) | Budesonid-pellets mit kontrolliertem freigabeprofil und verfahren zu ihrer herstellung | |
| DE69331948T2 (de) | Angenehm schmeckende pharmazeutische zusammensetzungen | |
| DD202505A5 (de) | Neue orale dipyridamolformen | |
| DE3420283A1 (de) | Nifedipin-trockenpraeparate und verfahren zu ihrer herstellung | |
| DE69620866T2 (de) | Vehrfahren zur herstellung von beta-lactam antibiotikum enthaltenden oralen dosisformen | |
| EP0306699A1 (de) | Dihydropyridin-Retard-Zubereitung | |
| DE69419281T2 (de) | Geschmacksmaskierte feste Zubereitung und Verfahren zur Herstellung | |
| LU84657A1 (de) | Neue kristallmodifikationen,verfahren zu deren herstellung und die sie enthaltenden pharmazeutischen zusammensetzungen | |
| EP0164588A2 (de) | Dihydropyridinpräparate und Verfahren zu ihrer Herstellung | |
| DE69825193T2 (de) | Pyridazinon-Verbindungen enthaltenden Zusammensetzungen zur oralen Verabreichung | |
| DE4245089B4 (de) | Stabilisiertes pharmazeutisches Mittel, enthaltend einen HMG-CoA-Reduktase-Inhibitor als Wirkstoff | |
| DE602006000402T2 (de) | Stabile Zubereitung enthaltend eine feuchtigkeitsemphindliche aktive Substanz und Verfahren zur Herstellung der Zubereitung. | |
| DE3419129A1 (de) | Nifedipinpraeparate und verfahren zu ihrer herstellung | |
| EP1663162B1 (de) | Oral zu applizierende darreichungsform für schwerlösliche saure und amphotere wirkstoffe | |
| EP1818050A1 (de) | Stabile pharmazeutische Zusammensetzungen umfassend einen HMG-CoA-Reduktase Inhibitor | |
| DE3419130A1 (de) | Nifedipinkombinationspraeparate und verfahren zu ihrer herstellung | |
| EP1532975B2 (de) | Verfahren zur Herstellung von freifliessenden, pulverförmigen Atorvastatin-Adsorbaten | |
| EP1259227A1 (de) | Verfahren zur herstellung von pharmazeutischen darreichungsformen | |
| EP1825848A2 (de) | Stabile pharmazeutische Zusammensetzungen umfassend einen HMG-CoA-Reduktase Inhibitor | |
| DD272797A5 (de) | Verfahren zur herstellung von festen arzneimittelzubereitungen mit langanhaltender wirkung fuer dihydropyridine | |
| CH627077A5 (en) | Pharmaceutical composition which foams in the intestine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8127 | New person/name/address of the applicant |
Owner name: NOVARTIS AG, BASEL, CH |
|
| 8128 | New person/name/address of the agent |
Representative=s name: SPOTT WEINMILLER & PARTNER, 80336 MUENCHEN |
|
| 8110 | Request for examination paragraph 44 | ||
| 8172 | Supplementary division/partition in: |
Ref document number: 4245089 Country of ref document: DE Kind code of ref document: P |
|
| Q171 | Divided out to: |
Ref document number: 4245089 Country of ref document: DE Kind code of ref document: P |
|
| AH | Division in |
Ref document number: 4245089 Country of ref document: DE Kind code of ref document: P |
|
| 8364 | No opposition during term of opposition | ||
| 8328 | Change in the person/name/address of the agent |
Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336 |
|
| R071 | Expiry of right | ||
| R071 | Expiry of right |